×
About 468 results

ALLMedicine™ Intermediate Uveitis Center

Research & Reviews  229 results

Classification criteria for multiple sclerosis-associated intermediate uveitis: Multipl...
https://doi.org/10.1016/j.ajo.2021.03.044
American Journal of Ophthalmology;

Apr 12th, 2021 - To determine classification criteria for multiple sclerosis-associated intermediate uveitis. Machine learning of cases with multiple sclerosis-associated intermediate uveitis and 4 other intermediate uveitides. Cases of intermediate uveitides were...

Classification criteria intermediate uveitis, non-pars planitis type.
https://doi.org/10.1016/j.ajo.2021.03.054
American Journal of Ophthalmology; Jabs DA, Denniston AK et. al.

Apr 11th, 2021 - To determine classification criteria for intermediate uveitis, non-pars planitis type (IU- NPP, also known as undifferentiated intermediate uveitis) DESIGN: : Machine learning of cases with IU-NPP and 4 other intermediate uveitides. Cases of inter...

Risk of Cataract in Intermediate Uveitis.
https://doi.org/10.1016/j.ajo.2021.02.032
American Journal of Ophthalmology; Minkus CL, Pistilli M et. al.

Mar 13th, 2021 - To determine the incidence of and predictive factors for cataract in intermediate uveitis. Retrospective cohort study METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, in which medi...

Intraocular solitary extramedullary plasmacytoma presenting as unilateral anterior and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846981
BMC Ophthalmology; Ayton T, Cherepanoff S et. al.

Jan 31st, 2021 - Solitary extramedullary plasmacytoma (SEP) is a localised proliferation of monoclonal plasma cells involving soft tissue with no or minimal bone marrow involvement and no other systemic evidence of multiple myeloma. Intraocular involvement is exce...

Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate...
https://doi.org/10.1016/j.ophtha.2020.10.036
Ophthalmology Suhler EB, Jaffe GJ et. al.

Nov 6th, 2020 - To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. Open-label, multicenter, phase 3 extension study (VISUAL III). Adults who had completed a random...

see more →

Clinicaltrials.gov  235 results

Classification criteria for multiple sclerosis-associated intermediate uveitis: Multipl...
https://doi.org/10.1016/j.ajo.2021.03.044
American Journal of Ophthalmology;

Apr 12th, 2021 - To determine classification criteria for multiple sclerosis-associated intermediate uveitis. Machine learning of cases with multiple sclerosis-associated intermediate uveitis and 4 other intermediate uveitides. Cases of intermediate uveitides were...

Classification criteria intermediate uveitis, non-pars planitis type.
https://doi.org/10.1016/j.ajo.2021.03.054
American Journal of Ophthalmology; Jabs DA, Denniston AK et. al.

Apr 11th, 2021 - To determine classification criteria for intermediate uveitis, non-pars planitis type (IU- NPP, also known as undifferentiated intermediate uveitis) DESIGN: : Machine learning of cases with IU-NPP and 4 other intermediate uveitides. Cases of inter...

Risk of Cataract in Intermediate Uveitis.
https://doi.org/10.1016/j.ajo.2021.02.032
American Journal of Ophthalmology; Minkus CL, Pistilli M et. al.

Mar 13th, 2021 - To determine the incidence of and predictive factors for cataract in intermediate uveitis. Retrospective cohort study METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study, in which medi...

Intraocular solitary extramedullary plasmacytoma presenting as unilateral anterior and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846981
BMC Ophthalmology; Ayton T, Cherepanoff S et. al.

Jan 31st, 2021 - Solitary extramedullary plasmacytoma (SEP) is a localised proliferation of monoclonal plasma cells involving soft tissue with no or minimal bone marrow involvement and no other systemic evidence of multiple myeloma. Intraocular involvement is exce...

Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate...
https://doi.org/10.1016/j.ophtha.2020.10.036
Ophthalmology Suhler EB, Jaffe GJ et. al.

Nov 6th, 2020 - To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. Open-label, multicenter, phase 3 extension study (VISUAL III). Adults who had completed a random...

see more →

News  4 results

FDA Clears Adalimumab (Humira) for Uveitis
https://www.staging.medscape.com/viewarticle/865654

Jun 30th, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.medscape.com/viewarticle/865654

Jun 30th, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Grants Orphan Drug Status to Gevokizumab
https://www.medscape.com/viewarticle/769952

Aug 28th, 2012 - August 29, 2012 — The US Food and Drug Administration (FDA) has granted orphan drug status to gevokizumab (Xoma 052, Xoma Corp), a monoclonal antibody that binds strongly to interleukin 1β (IL-1β), for the treatment of noninfectious intermediate u...

Systemic diseases associated with intermediate uveitis
https://www.mdedge.com/ccjm/article/92786/systemic-diseases-associated-intermediate-uveitis

Abstract BACKGROUND Intermediate uveitis is characterized by vitreal inflammation with associated inflammation of the vitreous base and peripheral anterior retina and choroid. It may be found as an isolated and idiopathic condition or in associati.

see more →